Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NSPRNASDAQ:SMTINASDAQ:SNWVNASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNSPRInspireMD$2.43-5.8%$2.64$2.07▼$3.80$74.44M0.6237,227 shs62,714 shsSMTISanara MedTech$35.10+2.1%$31.05$25.86▼$39.08$311.97M1.3825,955 shs23,815 shsSNWVSANUWAVE Health$33.26+8.9%$0.00$5.17▼$39.50$284.34M1.2530,407 shs67,805 shsSTIMNeuronetics$4.45+7.5%$4.22$0.52▼$5.92$292.90M1.92731,645 shs1.03 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNSPRInspireMD-0.77%-0.77%+0.78%-8.19%+15.44%SMTISanara MedTech+6.08%+6.21%+18.31%-0.41%+9.39%SNWVSANUWAVE Health+1.50%-1.32%+2.11%+3,054,999,900.00%+3,054,999,900.00%STIMNeuronetics-6.55%-8.00%+9.23%+5.34%+64.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNSPRInspireMD2.1872 of 5 stars3.50.00.00.01.72.50.6SMTISanara MedTech1.8154 of 5 stars3.51.00.00.01.91.70.6SNWVSANUWAVE HealthN/AN/AN/AN/AN/AN/AN/AN/ASTIMNeuronetics1.7308 of 5 stars3.32.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNSPRInspireMD 3.00Buy$4.5085.19% UpsideSMTISanara MedTech 3.00Buy$48.5038.18% UpsideSNWVSANUWAVE Health 0.00N/AN/AN/ASTIMNeuronetics 2.67Moderate Buy$5.5023.60% UpsideCurrent Analyst Ratings BreakdownLatest NSPR, SMTI, STIM, and SNWV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.003/26/2025SMTISanara MedTechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$46.00 ➝ $46.003/26/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $51.003/5/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNSPRInspireMD$7.01M10.62N/AN/A$1.83 per share1.33SMTISanara MedTech$86.67M3.60N/AN/A$5.22 per share6.72SNWVSANUWAVE Health$32.63M8.71N/AN/AN/A∞STIMNeuronetics$89.45M3.27N/AN/A$1.18 per share3.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ASMTISanara MedTech-$4.30M-$1.14N/AN/AN/A-10.71%-19.86%-10.91%5/14/2025 (Estimated)SNWVSANUWAVE HealthN/A-$4.56N/A∞N/AN/AN/AN/AN/ASTIMNeuronetics-$30.19M-$1.31N/AN/AN/A-50.09%-141.24%-32.77%N/ALatest NSPR, SMTI, STIM, and SNWV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SMTISanara MedTech-$0.31N/AN/AN/A$23.48 millionN/A5/9/2025Q1 2025SNWVSANUWAVE HealthN/A-$0.66N/A-$0.66N/A$9.34 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million3/25/2025Q4 2024SMTISanara MedTech-$0.19-$0.18+$0.01-$0.18$22.75 million$26.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNSPRInspireMDN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ASNWVSANUWAVE HealthN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNSPRInspireMDN/A6.396.05SMTISanara MedTech0.762.232.02SNWVSANUWAVE HealthN/AN/AN/ASTIMNeuronetics4.903.162.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNSPRInspireMD44.78%SMTISanara MedTech8.10%SNWVSANUWAVE Health42.53%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipNSPRInspireMD34.06%SMTISanara MedTech54.10%SNWVSANUWAVE Health36.60%STIMNeuronetics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNSPRInspireMD5030.64 million18.33 millionOptionableSMTISanara MedTech608.89 million4.01 millionNot OptionableSNWVSANUWAVE Health408.55 millionN/AN/ASTIMNeuronetics18065.82 million27.37 millionOptionableNSPR, SMTI, STIM, and SNWV HeadlinesRecent News About These CompaniesQ2 EPS Estimates for Neuronetics Reduced by William BlairMay 11 at 8:42 AM | marketbeat.comQ2 Earnings Estimate for Neuronetics Issued By William BlairMay 11 at 1:29 AM | americanbankingnews.comNeuronetics Announces Inducement Awards for New Team MembersMay 10 at 2:25 AM | msn.comNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83May 9, 2025 | finance.yahoo.comNeuronetics (NASDAQ:STIM) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPSMay 8, 2025 | marketbeat.comRenaissance Technologies LLC Has $255,000 Position in Neuronetics, Inc. (NASDAQ:STIM)May 8, 2025 | marketbeat.comEarnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%May 7, 2025 | investing.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin ChallengesMay 7, 2025 | finance.yahoo.comNeuronetics, Inc. (STIM) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comNeuronetics Reports First Quarter 2025 Financial and Operating ResultsMay 6, 2025 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 5, 2025 | globenewswire.comNeuronetics (STIM) Projected to Post Earnings on TuesdayMay 4, 2025 | americanbankingnews.comNeuronetics (STIM) to Release Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comWhy Neuronetics, Inc. (STIM) is Surging in 2025April 30, 2025 | msn.comNeuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6April 24, 2025 | msn.comNeuronetics, Inc. (NASDAQ:STIM) Sees Significant Growth in Short InterestApril 23, 2025 | marketbeat.comNeuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference CallApril 22, 2025 | tmcnet.comNeuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent DepressionApril 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitVertiv Crushes Q1 Estimates, Can the Stock Maintain Momentum?By Jeffrey Neal Johnson | April 28, 2025View Vertiv Crushes Q1 Estimates, Can the Stock Maintain Momentum?Visa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanBy Jeffrey Neal Johnson | May 3, 2025View Visa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanNSPR, SMTI, STIM, and SNWV Company DescriptionsInspireMD NYSE:NSPR$2.43 -0.15 (-5.81%) As of 04:00 PM EasternInspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Sanara MedTech NASDAQ:SMTI$35.10 +0.73 (+2.12%) As of 04:00 PM EasternSanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.SANUWAVE Health NASDAQ:SNWV$33.26 +2.71 (+8.87%) As of 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.Neuronetics NASDAQ:STIM$4.45 +0.31 (+7.49%) As of 04:00 PM EasternNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
